Previous close | 1.6000 |
Open | 5.6442 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 1.6000 - 1.6000 |
52-week range | 1.6000 - 1.6000 |
Volume | |
Avg. volume | N/A |
Market cap | 394,955 |
Beta (5Y monthly) | 1.36 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.8300 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
LYON, France, May 17, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the first quarter ended March 31, 2023.
LYON, France, May 16, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of the meeting notice for the Annual General Meeting, which will be held on June 21, 2023 at 9 am CEST at the Mercure Hotel, Lyon Centre Saxe Lafayette, 29 rue de Bon
LYON, France, May 15, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced TWYMEEG® (Imeglimin) Fiscal Year (FY) and fourth quarter 2022 results, as recently published by Sumitomo Pharma (Sumitomo), its partner commercializing TWYMEEG in Japan.
LYON, France, May 11, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the JMP Securities Life Science Conference, to be held in New York, NY, Monday, May 15, and Tuesday, May 16, 2023.
LYON, France, May 03, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced that the Universal Registration Document (Document d’Enregistrement Universel) for the year ended December 31, 2022 has been filed with the French market authority (Autorité des Marchés Financ
LYON, France, April 20, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today that nine abstracts based on Imeglimin Phase 2b and Phase 3 clinical trials have been accepted for oral presentations at the 66th Annual Meeting of the Japanese Diabe
LYON, France, March 23, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its results for the year ended December 31, 2022 and provided a corporate update.
LYON, France, March 23, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today that is has finalized (1) agreements with its lenders to restructure its existing debt obligations and (2) a new equity-linked financing with IRIS with an initial drawdown of EUR 3
LYON, France, March 22, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced it will report its 2022 Full year results on March 23, 2023, before market opening.
LYON, France, March 22, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today that it will report its 2022 full year results by the end of March 2023.
LYON, France, March 15, 2023--Regulatory News: POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the NASH Renaissance virtual event hosted by Evercore ISI on Thursday, March 30, 2023.
LYON, France, March 07, 2023--Regulatory News: POXEL SA (Euronext : POXEL – FR0012432516), clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced publication in Journal of Hepatology of positive results for DESTINY-1 (Deuterium-stabilized R-pioglitazone [PXL065] Efficacy and Safety Trial In NASH), a 36-week dose-ranging Phase
LYON, France, March 01, 2023--Regulatory News: POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today the publication of preclinical results in autosomal dominant polycystic kidney disease (ADPKD) for PXL770, a novel, first-in-class direct adenosine monophosphate-acti
LYON, France, February 15, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its cash position and revenue and provided a corporate update for the twelve months ended December 31, 2022.
LYON, France, January 25, 2023--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that European Commission has granted orphan drug designation (ODD) for PXL770 and PXL065 for the treatment of adrenoleukodystrophy (ALD). The decision follows a positive opinion from the Committ
LYON, France, January 04, 2023--POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its upcoming participation at conferences organized by Oddo BHF and Degroof Petercam to be held in January 2023.
LYON, France, January 03, 2023--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2023.
LYON, France, December 22, 2022--POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced the drawdown of the remaining two tranches of the convertible bonds as part of the equity-linked financing facility with Iris Capital Investment (IRIS) representing a total of EUR 2 million.
LYON, France, November 08, 2022--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the third quarter and the nine months ended September 30, 2022.
LYON, France, November 07, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that the results from its Phase 2 study of PXL065 in NASH (DESTINY-1) were presented during the late-breaking session at The Liver Meeting® 2022, hosted by the American Association for the Study
LYON, France, November 07, 2022--POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the Jefferies London Healthcare Conference, to be held in London from Tuesday, November 15 to Thursday, November 17, 2022.
LYON, France, October 13, 2022--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that it is presenting at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference on Monday, October 17th, 2022 at 10:00 am ET (4:00 pm CEST). Thomas Kuhn, CEO of Poxel, and other members
LYON, France, October 12, 2022--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that its late-breaking abstract describing the results from its Phase 2 study of PXL065 in NASH (DESTINY-1) has been selected for an oral presentation at The Liver Meeting® 2022, hosted by the A
LYON, France, October 04, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic diseases, today announces the publication of its half-year financial report as of June 30, 2022.
LYON, France, October 03, 2022--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to PXL770 for the treatment of patients with autosomal-dominant polycystic kidney disease (ADPKD). PXL7